

## Your abstract submission has been received

Print this page

You have submitted the following abstract to the ASRM 2025 Scientific Congress & Expo. Receipt of this notice does not guarantee that your submission was complete or free of errors.

---

### FROZEN EMBRYO TRANSFER OUTCOMES IN PATIENTS WITH PRIOR UTERINE ARTERY EMBOLIZATION

Emily A Clarke, M.D.<sup>1</sup>, Atoosa Ghofranian, M.D.<sup>1</sup>, Charlotte Jones, BA<sup>2</sup>, Morgan Baird, MPH<sup>2</sup>, Luis R Hoyos, M.D.<sup>3</sup>, Meike L Uhler, M.D.<sup>4</sup>, Michael Vance Homer, M.D.<sup>5</sup>, Joseph A. Lee, BA<sup>2</sup>, Kathleen Devine, MD<sup>6</sup> and Alan B. Copperman, M.D.<sup>7</sup>, (1)Icahn School of Medicine at Mount Sinai, New York, NY, (2)Reproductive Medicine Associates of New York, New York, NY, (3)IVF Florida, (4)Fertility Centers of Illinois, Chicago, IL, (5)Reproductive Science Center, (6)Shady Grove Fertility, Rockville, MD, (7)Icahn School of Medicine at Mount Sinai / Reproductive Medicine Associates of New York, New York, NY

**Title:**

FROZEN EMBRYO TRANSFER OUTCOMES IN PATIENTS WITH PRIOR UTERINE ARTERY EMBOLIZATION

**Submitter's E-mail Address:**

emilyclarkemd@gmail.com

**Preferred Presentation Type:**

Oral or Poster

**Study Type:**

Case Series/ Case Report

**Category - Subcategory(ies):**

**Benign Gynecological Disease:** Fibroids

**References:**

1 Karlsen K et al. Fertility after uterine artery embolization of fibroids: a systematic review. Arch Gynecol Obstet. 2018;297(1):13-25.

2 Serres-Cousine O, et al. Clinical investigation of fertility after uterine artery embolization. Am J Obstet Gynecol. 2021 Oct;225(4):403.e1-403.e22.

**\* Submission of an abstract for consideration for presentation implies that the presenting author & associated co-authors have legal and ethical rights to submit and present this work. Plagiarism and submitting work that an author has no rights to, will result in an investigation and penalty.**

**\* I verify that I am in compliance with HIPAA standards to protect the privacy of the patients discussed in my presentation(s). I either have received written authorization from the patient, have removed any identifiable images or patient records from my presentation, or my presentation does not pertain to patient treatment.**

**Permissions - Prior Publication or Presentation**

This abstract contains original work, not published or presented previously at a meeting of another national or international scientific organization prior to this meeting and has not been submitted for publication at the time of this submission.

**ACCME Disclosure**

Nothing to disclose. No off-label or otherwise non-approved product use.

**Did this abstract require approval by a local Institutional Review Board (IRB) or equivalent?**

This abstract has been approved by a local Institutional Review Board (IRB) or equivalent.

**Applying for an award**

**Trainee: Yes**

**Abstract Category:**

All Other Categories

## Applied for the In-Training Award for Research

### Abstract Text:

**OBJECTIVE:** The sequelae of uterine artery embolization (UAE) on future reproductive outcomes remains unclear, with studies reporting reduced fertility following UAE for treatment of fibroids [1,2]. Additionally, in patients who undergo UAE to treat postpartum hemorrhage (PPH), limited research has evaluated subsequent reproductive outcomes. Notably, no study has described frozen embryo transfer (FET) cycle outcomes after UAE. This study aims to evaluate FET outcomes in patients following UAE for either fibroid treatment or PPH.

**MATERIALS AND METHODS:** This multicenter study included patients with a history of UAE for fibroid treatment or PPH who underwent a subsequent FET cycle between January 2016 and December 2024. Only patients who underwent a single embryo FET cycle were included. The primary outcome was live birth. Secondary outcomes included proportion of cycles with thin endometrial lining (<7mm), live birth rate per patient (# patients who achieved live birth / # patients), and positive pregnancy, clinical pregnancy, biochemical loss, and clinical loss per FET. Descriptive statistics were used to summarize the data, with continuous variables reported as means with standard deviations and categorical variables as proportions.

**RESULTS:** A total of 50 FET cycles were included, consisting of 33 patients with a history of UAE. Of these, 19 patients underwent UAE for fibroid treatment (29 FET cycles) and 14 patients underwent UAE for treatment of PPH (21 FET cycles). Oocyte age was comparable between groups (fibroids: 34.4±5.7 years, PPH: 34.9±3.7 years). FET outcomes are shown in Table 1. Live birth per FET was 24.1% in patients who underwent UAE for fibroids and 47.6% in those treated for PPH. Live birth rate per patient was similarly lower in the fibroid group (31.6%) compared to the PPH group (64.3%). The proportion of patients with thin endometrial lining was similar between groups (fibroids: 17.2%, PPH: 19.0%).

**CONCLUSIONS:** Patients who underwent UAE for fibroid treatment had lower rates of FET cycle success, whereas those treated for PPH did not experience lower success rates. Regardless of indication, UAE may be associated with thin endometrium, as a notable proportion of patients in both groups experienced endometrial lining <7mm.

**IMPACT STATEMENT:** While a history of UAE for fibroid treatment is associated with poorer FET outcomes, patients treated for PPH can be reassured that their indication does not appear to reduce the likelihood of achieving live birth following FET.

Table 1. FET outcomes following UAE

	Fibroids (n=29)	PPH (n=21)
Positive Pregnancy (%)	48.3	61.9
Clinical Pregnancy (%)	37.9	57.1
Live Birth (%)	24.1	47.6
Biochemical Loss (%)	10.3	4.8
Clinical Loss (%)	13.8	9.5

First Presenting Author

**Presenting Author**

---

Emily A Clarke, M.D.

**Email:** emilyclarkemd@gmail.com -- Will not be published

Icahn School of Medicine at Mount Sinai  
Obstetrics, Gynecology, and Reproductive Science  
1176 Fifth Ave, Klingenstein Pavilion  
9th floor  
New York NY 10029  
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?

No

Signature: Emily Clarke, MD



**CV Upload:**

 [Emily Clarke CV 02.2025.docx](#)

Second Author

---

Atoosa Ghofranian, M.D.

**Email:** aghofranian@rmany.com -- Will not be published

Icahn School of Medicine at Mount Sinai  
Obstetrics, Gynecology, and Reproductive Science  
1176 Fifth Ave, Klingenstein Pavilion  
9th Floor  
New York NY 10029  
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?

No

Signature: Atoosa Ghofranian, M.D.

**CV Upload:**

 [CV 2021.pdf](#)

Third Author

---

Charlotte Jones, BA

**Email:** Charlotte.aurora.j@gmail.com -- Will not be published

Reproductive Medicine Associates of New York  
635 Madison Ave 10th Fl  
New York NY 10022-1009  
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?

No

Signature: Charlotte Jones

#### Fourth Author

---

Morgan Baird, MPH

**Email:** mbaird@rmaofny.com -- Will not be published

Reproductive Medicine Associates of New York  
635 Madison Avenue  
10th Fl.  
New York NY 10022-1009  
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?

No

Signature: Morgan Baird, MPH

#### Fifth Author

---

Luis R Hoyos, M.D.

**Email:** luis.hoyos@ivfflorida.com -- Will not be published

IVF Florida

Within the past 2 years, have you or your spouse/partner had any potential COI?

No

Signature: Luis Hoyos, M.D.



Sixth Author

---

Meike L Uhler, M.D.

**Email:** meike.uhler@fcionline.com -- Will not be published

Fertility Centers of Illinois  
Chicago IL  
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?

No

Signature: Meike Uhler, MD

Seventh Author

---

Michael Vance Homer, M.D.

**Email:** michael.homer@rscbayarea.com -- Will not be published

Reproductive Science Center

Within the past 2 years, have you or your spouse/partner had any potential COI?

Yes

Organization Name	Relationship Type	Who has this Relationship?	
Alife	Paid Consultant Relationship Began - Monday, April 8, 2024 Relationship Ended -	Self	

Organization Name	Relationship Type	Who has this Relationship?
Ferring Pharmaceutical	Speaker's Bureau Relationship Began - Saturday, March 1, 2025 Relationship Ended -	Self
Lovu Health	Direct Stockholder Relationship Began - Saturday, June 1, 2024 Relationship Ended -	Self
U. S. Fertility	Direct Stockholder Relationship Began - Saturday, August 1, 2020 Relationship Ended -	Self
USF Pharmaceutical Contracting Alliance	Direct Stockholder Relationship Began - Wednesday, January 1, 2020 Relationship Ended -	Self

Signature: Michael Vance Homer, M.D..

#### Eighth Author

---

Joseph A. Lee, BA

**Email:** jlee@rmany.com -- Will not be published

Reproductive Medicine Associates of New York  
Director of Research Ops  
635 Madison Ave 10th Fl  
New York NY 10022-1009  
USA

Biographical Sketch Early success, marked by his first publication in CELL at Harvard Medical School, inspired Joseph to continue his research endeavors in reproductive endocrinology and infertility. Joseph has been with Reproductive Medicine Associates of New York since 2011. Joseph has authored over 400 peer-reviewed abstracts & manuscripts. Passionate about development, he cultivates relationship with investors & entrepreneurs to advance reproductive endocrinology & infertility care.

Within the past 2 years, have you or your spouse/partner had any potential COI?

No

Signature: Joseph Adam Lee



**CV Upload:**

 [Joseph Lee CV.docx](#)

Ninth Author

---

Kathleen Devine, MD

**Email:** [kdevine@gmail.com](mailto:kdevine@gmail.com) -- Will not be published

Shady Grove Fertility  
Physician  
Rockville MD  
USA

Biographical Sketch Kate Devine, M.D. serves as US Fertility's Medical Director and Chief Research officer and endeavors to expand the knowledge base of our field on behalf of patients striving to achieve their dreams of family. Dr. Devine supports the faculty of the six USF-affiliated Reproductive Endocrinology and Infertility fellowships. Furthermore, she oversees a culture of excellence in the medical care of our patients across the USF Network. Dr. Devine, a board-certified Reproductive Endocrinologist, cares for patients in Washington, D.C., and has served as Research Director at Shady Grove Fertility for nearly a decade. She is Clinical Professor of Obstetrics and Gynecology at George Washington University and Associate Program Director for the Reproductive Endocrinology and Infertility Fellowship at the National Institutes of Health (NIH). Dr. Devine serves as Chair of the Society for Reproductive Endocrinology and Infertility (SREI) Research Committee, Chair of the Society for Assisted Reproductive Technology (SART) Quality Assurance Committee, and on the Editorial Board of Fertility and Sterility. She has authored more than 50 peer-reviewed publications, has received numerous research grants and awards, including the 2023 ASRM New Investigator Award, and has spoken nationally and internationally on the topic of her research, which focuses primarily on endometrial receptivity and optimization of frozen embryo transfer protocols. She earned her BA from Columbia University and MD from Albert Einstein College of Medicine. She completed residency at New York University Medical Center and fellowship at the NIH.

Within the past 2 years, have you or your spouse/partner had any potential COI?

No

Signature: Kathleen Devine, MD



**CV Upload:**

 [K Devine CV 3.16.24.docx](#)

Tenth Author

---

Alan B. Copperman, M.D.

**Email:** [acopperman@rmany.com](mailto:acopperman@rmany.com) -- Will not be published

Icahn School of Medicine at Mount Sinai / Reproductive Medicine Associates of New York  
Department of Obstetrics, Gynecology, and Reproductive Science  
New York NY  
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?

Yes

Organization Name	Relationship Type	Who has this Relationship?	
Progyny	Company Officer Relationship Began - Friday, August 25, 2017 Relationship Ended - Thursday, June 1, 2023 Paid Consultant Relationship Began - Relationship Ended - Direct Stockholder Relationship Began - Friday, August 25, 2017 Relationship Ended - Friday, November 1, 2024	Self	

Signature: Alan B Copperman



**CV Upload:**

 [Alan B. Copperman M.D. - CV \(March 2024\).docx](#)

---

**If necessary, you can make changes to your abstract submission until Wednesday, April 30, 2025 at 4:00 pm (EDT).**

To access your submission in the future, use the link to your user portal from one of the automatic confirmation emails that were sent to you during the submission.

Or point your browser to <https://asrm.confex.com/asrm/2025/gateway.cgi>

You will be prompted to login with your ASRM account prior to accessing the user portal. If you do not yet have an ASRM account, the screen will redirect you to the site where you can register for a new account. When registering for a new ASRM account:

- Please use the email address that is associated with the submission and your first and last name as they appear on the submission when creating this account.
- An ASRM account for login must be completed before you can access the user portal.

Any changes that you make will be reflected instantly in what is seen by the reviewers. You DO NOT need to go through all of the submission steps in order to change one thing. If you want to change the title, for example, just click "Title" in the abstract control panel and submit the new title.

When you have completed your submission, you may close this browser window.

If you would like to submit another abstract, click [here](#).

[Tell us what you think of the abstract submission process](#)

[Home Page](#)